GLP-1 medications show promise in slowing kidney disease progression
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
Medscape8d
New Data Shed Light on Who Stops Using GLP-1 Drugs, and Why
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
Endocrinology Advisor1d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
HealthDay on MSN3d
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...
News Medical on MSN7d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Daily8h
Elective Peri-Operative Management of Patients on GLP-1, GIP Agonists & SGLT-2 Inhibitors: Multidisciplinary Consensus Released
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
Morningstar11d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...